IGHE and neoplasm: Preclinical comparison of anti-tumour activity using an IgE or an IgG antibody, each specific for the same target antigen, has demonstrated that the efficacy of IgE is indeed superior, both in human tumour xenograft-bearing mouse models10–13 and in an immunocompetent rat model of metastatic cancer14,15.